Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2025)

Crinetics Pharmaceuticals has reported Interest & Investment Income over the past 9 years, most recently at $11.2 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $11.2 million for Q4 2025, down 22.36% from a year ago — trailing twelve months through Dec 2025 was $52.0 million (up 25.47% YoY), and the annual figure for FY2025 was $52.0 million, up 25.47%.
  • Interest & Investment Income for Q4 2025 was $11.2 million at Crinetics Pharmaceuticals, down from $12.5 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CRNX hit a ceiling of $14.8 million in Q1 2025 and a floor of $23000.0 in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $2.3 million (2023), compared with a mean of $5.6 million.
  • Biggest five-year swings in Interest & Investment Income: tumbled 94.6% in 2021 and later surged 6150.0% in 2022.
  • Crinetics Pharmaceuticals' Interest & Investment Income stood at $80000.0 in 2021, then skyrocketed by 2280.0% to $1.9 million in 2022, then skyrocketed by 253.05% to $6.7 million in 2023, then skyrocketed by 113.75% to $14.4 million in 2024, then dropped by 22.36% to $11.2 million in 2025.
  • The last three reported values for Interest & Investment Income were $11.2 million (Q4 2025), $12.5 million (Q3 2025), and $13.5 million (Q2 2025) per Business Quant data.